Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Profit After Tax: 2023-2025

Historic Profit After Tax for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Profit After Tax fell 153.26% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.8 million, marking a year-over-year decrease of 80.04%. This contributed to the annual value of -$95.5 million for FY2024, which is 49.45% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Profit After Tax of -$19.7 million as of Q3 2025, which was up 34.94% from -$30.3 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Profit After Tax ranged from a high of $37.0 million in Q3 2024 and a low of -$65.7 million during Q4 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median Profit After Tax value was -$39.2 million (recorded in 2023), while the average stood at -$32.5 million.
  • In the last 5 years, Day One Biopharmaceuticals' Profit After Tax soared by 180.25% in 2024 and then tumbled by 588.04% in 2025.
  • Quarterly analysis of 3 years shows Day One Biopharmaceuticals' Profit After Tax stood at -$54.5 million in 2023, then dropped by 20.55% to -$65.7 million in 2024, then plummeted by 153.26% to -$19.7 million in 2025.
  • Its Profit After Tax was -$19.7 million in Q3 2025, compared to -$30.3 million in Q2 2025 and -$36.0 million in Q1 2025.